Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

NCT ID: NCT05688280

Last Updated: 2025-01-08

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-29
• Study Completion Date: 2025-02-28

Brief Summary

The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.

Detailed Description

The therapeutic approach taken by this clinical trial may offer patients a therapeutic benefit after failure of standard chemotherapy and immunotherapy.

Patients giving written informed consent will undergo screening during the Pretreatment Period to determine eligibility for trial entry. The Pretreatment Period will include collection and recording of medical history, concomitant medications, baseline symptoms, previous therapies, and baseline assessments. The patient's baseline tumor burden will be recorded with radiological assessments, along with analyzing location and size of tumors to identify and characterize target tumor(s) that will be treated and/or followed during the clinical trial.

If confirmed eligible for the study, the patient will advance into the Treatment Period. During the Treatment Period, patients will receive a routine radiofrequency ablation (RFA), followed by an injection of investigational product (IP-001 for Injection) into the tumor. Patients can be treated every 6 weeks for up to 4 treatments with RFA + IP-001 for Injection.

A patient will move to the 6-month Follow-up Period when the patient has completed 4 treatment cycles or if the decision is made that no subsequent treatments will be administered. During the Follow-up Period, there will be a Follow-up Visit every 6 weeks for 5 visits, at disease progression, or prior to the start of a new antineoplastic treatment.

Conditions

Metastatic Solid Tumor; Colon Cancer; Nonsmall Cell Lung Cancer; Soft Tissue Sarcoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Colorectal Cancer (CRC)

Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.

Group Type: EXPERIMENTAL

1.0% IP-001 for Injection

Intervention Type: DRUG

4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Non-Small Cell Lung Cancer (NSCLC)

Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.

Group Type: EXPERIMENTAL

1.0% IP-001 for Injection

Intervention Type: DRUG

4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Soft Tissue Sarcoma (STS)

Radiofrequency ablation (RFA) followed by an intratumoral injection of IP-001.

Group Type: EXPERIMENTAL

1.0% IP-001 for Injection

Intervention Type: DRUG

4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Interventions

1.0% IP-001 for Injection

4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Intervention Type: DRUG

Other Intervention Names

IP-001

Eligibility Criteria

Inclusion Criteria

1. Stage 3 or Stage 4 CRC, NSCLC, or STS who have failed, are ineligible, refused, or become intolerant to at least first line (but no more than 4 lines) of systemic therapy

2. Life expectancy of > 6 months. Only have lesions with the longest diameter of ≤ 5 cm.

3. Presence of at least one non-bone tumor lesion that is ablation-accessible, with a minimum size of 1.0 cm.

4. Measurable disease according to RECIST 1.1.

5. Age ≥ 18 years.

6. ECOG performance status 0-1.

7. Bone marrow function: neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, hemoglobin ≥ 90 g/L.

8. Adequate hematological function defined by white blood cell count ≥ 2.5 × 109/L with absolute neutrophil count ≥ 1.5 × 109/L, and hemoglobin ≥ 9 g/dL (transfusions allowed on study).

9. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and aspartate transaminase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN for all patients, or for patients with documented metastatic disease to the liver and AST and ALT levels ≤ 5 × ULN. Patients with documented Gilbert disease are allowed if total bilirubin is less than 3 × ULN.

10. Adequate renal function defined by an estimated creatinine clearance ≥ 50 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).

11. Men and women with childbearing potential agree to use effective contraception. Women of childbearing potential must have a negative pregnancy test (serum) before inclusion.

Exclusion Criteria

1. Known allergic reaction to shellfish, crabs, crustaceans, or any trial components, used in trial treatment.

2. Malignant primary brain tumors or evidence of brain metastases or leptomeningeal disease.

3. Patients who have received chemotherapy, radiotherapy, immunotherapy, or concurrent or recent treatment with any other investigational agents within 21 days prior to treatment.

4. Patients who have not recovered to common terminology criteria for adverse events (CTCAE) Grade ≤ 1 from all side effects of prior therapies except for residual toxicities.

5. Patients with a history of malignancy, with the exception of non-melanoma skin cancers and in situ cancers.

6. Concomitant treatment with systemic corticosteroids (10 mg prednisolone or equivalent) or other immunosuppressive therapy.

7. Anti-coagulation therapies which cannot be stopped 24 hours prior to trial treatment.

8. Severe or uncontrolled cardiovascular disease (congestive heart failure New York Heart Association classification III or IV).

9. Documented HIV positive.

10. Active Hepatitis C or Hepatitis B Viral infection.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Immunophotonics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Markus Jorger, MD

Role: PRINCIPAL_INVESTIGATOR

Cantonal Hospital of St. Gallen

Diane Beatty, PhD

Role: STUDY_DIRECTOR

Immunophotonics, Inc.

Locations

Miami Cardiac & Vascular Institute

Coral Gables, Florida, United States

University of Louisville Physicians, PSC

Louisville, Kentucky, United States

Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

Institut Bergonie

Bordeaux, , France

Hospitalier Pitie-Salpetriere

Paris, , France

Hôpital Foch

Suresnes, , France

Institut Gustave Roussy

Villejuif, , France

Johann Wolfgang Goethe-Univresitat Frankfurt/Main

Frankfurt, , Germany

SLK-Kliniken Heilbronn GmbH

Heilbronn, , Germany

Munchen Klinik Bogenhausen

Munich, , Germany

IOSI Ospedale San Giovanni Bellinzona

Bellinzona, , Switzerland

Inselspital Universitatsspital, Bern

Bern, , Switzerland

Kantonsspital Graubunden

Chur, , Switzerland

Kantonsspital St. Gallen

Sankt Gallen, , Switzerland

University College London Hospitals

London, , United Kingdom

Churchill Hospital

Oxford, , United Kingdom

Countries

United States; France; Germany; Switzerland; United Kingdom

Other Identifiers

IP-IIO-622

Identifier Type: -

Identifier Source: org_study_id